Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy ...